Studies
-
Completion
Visceral Leishmaniasis (VL) and Maternal Health in Lankien, Jonglei state, South Sudan
Principal investigator: Judith PekelharingLatest update: 8th August 2022Impact: No update added by Judith pekelharing | 25th Sep 2020
-
Completion
Visceral Leishmaniasis (VL) and Maternal Health in Lankien, Jonglei state, South Sudan
Principal investigator: Judith PekelharingLatest update: 8th August 2022Impact: No update added by Judith pekelharing | 25th Sep 2020
-
Completion
Visceral Leishmaniasis (VL) and Maternal Health in Lankien, Jonglei state, South Sudan
Principal investigator: Judith PekelharingLatest update: 8th August 2022Impact: No update added by Judith pekelharing | 25th Sep 2020
-
Implementation
Cutaneous leishmaniasis patient characteristics and treatment outcomes, Quetta Pakistan 2014-2020
-
Archived
The impact of highly active antiretroviral choices on the outcomes of visceral leishmaniasis in Ethiopia
Archived by: Holly Baker | 9th August 2022
-
Archived
Visceral Leishmaniasis as an AIDS Defining Condition: Towards Consistency across WHO Guidelines
Archived by: Holly Baker | 8th August 2022
-
Archived
Retrospective cohort analysis of HIV/VL coinfected patients treated with AmBisome + Miltefosine combination therapy
Archived by: Holly Baker | 10th August 2022
-
Withdrawn or Postponed
A randomized trial of AmBisome monotherapy and combination of AmBisome and miltefosine for the treatment of VL in HIV positive patients in Ethiopia
Principal investigator: Koert RitmeijerLatest update: Principal investigator changed by Kim West | 7th October 2016
-
Implementation
PreLeish: Predicting Visceral Leishmaniasis in HIV Infected Patients
Principal investigator: Koert RitmeijerLatest update:ERB supporting documents added by Koert Ritmeijer| 14th July 2020
-
Archived
Effectiveness and safety of thermotherapy with the low-cost HECT-CL device in the treatment of Cutaneous Leishmaniasis in Quetta, Pakistan.
Archived by: Sree | 27th July 2022
-
Completion
Effectiveness of Sodium Stibogluconate Monotherapy to Sodium Stibogluconate and Paromomycin Combination for the Treatment of Severe PKDL in South Sudan
Principal investigator: Charles AbongomeraLatest update: 1st August 2022Impact: Programmes added by Koert ritmeijer | 28th Sep 2020
-
Archived
Active and passive case detection strategies for control of leishmaniasis in Bangladesh
Archived by: Holly Baker | 10th August 2022
-
Withdrawn or Postponed
clinical and anthropometric characteristics of patients with visceral leishmaniasis in Amhara region, Ethiopia, in the most endemic foci (Libo Kemken, Gondar, Metema and Abdurafi), and relevancy of results in the control program management
Principal investigator: Koert RitmeijerLatest update: Study was withdrawn or postponed | 25th September 2018
-
Archived
Hypokalemia in patients treated with AmBisome for Post-Kala azar Dermal Leishmaniasis (PKDL) in Bangladesh
Archived by: Holly Baker | 28th July 2022
-
Archived
Secondary prophylaxis of visceral leishmaniasis relapses in HIV co-infected patients using pentamidine as a prophylactic agent: a prospective cohort study
Archived by: Holly Baker | 10th August 2022
-
Archived
Utilizing remote sensing to explore environmental factors of visceral leishmaniasis in South Sudan
Archived by: Holly Baker | 10th August 2022
-
Archived
A Screen-and-Treat Strategy Targeting Visceral Leishmaniasis in HIV Infected Individuals in Endemic East African Countries: The Way Forward?
Archived by: Holly Baker | 10th August 2022
-
Completion
A clinical prognostic tool for mortality in Visceral Leishmaniasis in a high HIV co-infection burden area in Ethiopia
Principal investigator: Charles AbongomeraLatest update: 1st August 2022Impact: Programmes added by Koert ritmeijer | 28th Sep 2020